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Prediction of amikacin dose requiretnents in neutropenic
patients with haetnatological disease
C. S. ZENT, R. ALLIN, P. I. FOLB
Abstract This study reports on the use of an easily applied
Bayesian forecasting ptogranune (OPT; Clyde-
soft) to predict atnikacin dose requirements in 10
patients with haematological disease and neu-
tropenic fever. OPT-determined dose adjustment
achieved therapeutic drug levels for 80% of the
peak and 940/0 of the trough measurements.
S Afr Med J 1993; 83: 853-854.
~
inOglYCOSides have a narrow therapeutic index
and are potentially nephrotoxic and ototoxic. The
achievement of therapeutic serum levels is diffi-
cult because of individual kinetic variability.' We applied
a simple but accurate predictive model to the clinical
care of neutropenic patients in whom aminoglycoside
kinetics may be significantly altered. 2
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Patients and methods
Ten consecutive patients with haematological disorders
were studied in the Department of Haematology,
Groote Schuur Hospital, between I°June and 27
August 1990. Patients were included in the study if they
satisfied criteria for neutropenic fever and required
antibiotic therapy according to the standard .manage-
ment protocol.
Amikacin therapy was initiated by the treating physi-
cians who decided on the initial dose. Amikacin sul-
phate (Amikin; Bristol) was administered intravenously
over 30 minutes in 0,9% saline or 5% dextrose water.
Blood for amikacin assay was taken 1 hour after com-
mencement of dose administration (peak level) and a
second sample at 3 hours in 5 patients, 5 hours in 2
patients, and immediately before the next dose in 3
patients. Peak and trough levels (measured 5 minutes
before drug administration) were then measured at least
twice weekly or more frequently if impaired renal func-
tion developed (a rise in serum creatinine level greater
than 40 flIIloIll). Specimens were assayed for amikacin
within 12 hours of collection by the Abbott TDX
Polarised Fluorescent antibody method. The lower limit
of sensitivity is 0,8 mg/l and levels below this were
recorded as 0,4 mg/I. Amikacin phannacokinetic para-





Pt Dose Peak PRPK ME MAE RMSE Trough PRTA ME MAE RMSE
1 11,9 34,6 28,1 1,2 6,9 7,9 8,7 3,8 4,9 4,9 6,0
2 11,3 29,3 26,6 2,7 4,5 5,5 2,0 1,2 0,8 1,0 1,4
3 9,3 26,0 27,4 -1,4 4,0 4,6 1,3 1,0 0,3 0,7 0,9
4 11,5 30,3 31,8 -1,5 4,3 5,6 1,2 0,6 0,6 0,7 0,8
5 9,1 28,1 34,8 -6,7 6,7 6,9 2,9 3,8 -0,9 1,4 2,4
6 9,1 30,6 22,4 8,2 8,2 8,5 2,4 1,0 1,4 2,3 2,5
7 11,7 36,6 26,2 10,4 10,4 10,8 2,8 1,4 1,5 1,5 1,9
8 8,6 22,3 25,S -3,1 4,9 6,0 4,3 2,4 1,9 1,9 2,0
9 9,8 31,8 29,1 2,8 8,4 8,8 1,5 0,4 1,7 1,7 1,7
10 12,2 31,3 29,1 2,3 6,7 9,1 2,2 0,8 1,0 1,5 1,8
Average 10,5 30,1 28,1 1,5 6,5 7,4 2,9 1,6 1,3 1,8 2,1
Pt ; subject patient number; dose; mean of administered dose of amikacin in mglkg actual body weight; peak; mean achieved peak drug level in mg/!; PRPK ; mean
predicted peak level derived from OPT in mg/!; ME ; mean error of prediction (achieved - predicted level in mg/!); MAE ; mean absolute error; trough; mean
achieved trough level in mg/!; PRTR ; mean predicted trough level derived from OPT in mg/!.
ware package (Clydesoft)3 on a personal compurer.
OPT is based on Bayesian statistical probability theory
and assumes a single-compartment kinetic model for
amikacin. Individual patient kinetics are initially esti-
mated as follows: age, sex, weight, height and serum
creatinine level are entered into a population-based
nomogram and these estimates are sequentially modi-
fied according ro the following data input: dose size,
time of administration, serum level and sampling time.
Data input is time-weighted and additional significance
is attributed to the most recent input.
Derived parameters were then used to predict dose
size and the frequency required to achieve peak levels of
30 ± 10 mg/I and trough levels not exceeding 6 mg/l.
Appropriate dose changes were made within 24 hours of
each serum level assay. The accuracy of this approach
was assessed by comparison of the predicted with the
achieved results. Bias was measured by calculating mean
error (ME) and precision by calculating mean absolute
error (MAE) and root mean squared error (RMSE).
The method was regarded as unbiased if the 95% confi-
dence interval (Cl) for mean error (Thompson's test)
included 0 and precise if the MAE and RMSE were
< 8 mg/l for peak and < 4 mgll for trough levels. These
criteria are based on those of previously published stud-
ies that used gentamicin, tobramycin and netilmicin/ a
conversion facror of 4 was used to derive the limits for
amikacin.
Results (Table I)
There were 1°patients (6 male and 4 female); their
mean age was 32 years (range 15 - 60), and their mean
minimum neutrophil count during therapy 0,05 x 10'/1.
Fifty-one pairs of predicted and achieved levels were
evaluated; this required 38 batches of amikacin assays.
The mean control value (±SD) was 14,7 ± 0,5 mg/l
(range 13,9 - 15,6).
The mean amikacin dose requirement was 10,5
mglkg/dose (range 9,1 - 12,2). The mean (±SD) of the
average amikacin levels achieved for each patient was
30,1 ± 4,1 mgll for peak and 2,9 ± 2,2 mgll for trough
levels; ME for peak levels = 1,5 mg/l (95% Cl -2,6 - 6,5
mg/I), MAE = 6,5 mg/l and RMSE = 7,4 moo I. Peak
level predictions were thus unbiased (95% Cl for ME
includes 0) and precise (MAE and RMSE < 8 mg/I).
ME of prediction for trough levels = 1,3 (95% Cl
0,4 - 1,8). MAE = 1,8 and RM.SE = 2,1. Trough level
predictions were biased (95% Cl did not include 0) but
precise (MAE and RMSE < 4 mg/l).
Therapeutic peak levels (20 - 40 mg/l) were achieved
for 80% of predictions and non-toxic trough levels (nor
exceeding 6 mg/l) for 94% of predictions.
Therapeutic peak and trough levels were achieved in
7 patients (70%) after the first kinetic prediction. One
patient had toxic peak and trough levels, one had a toxic
peak level only and one had sub-therapeutic peak levels.
Discussion
The predictive accuracy achieved in this study compares
well \vith that reponed for this method in non-neutro-
penic patients· and with the use of a non-Bayesian
method in neutropenic patients.' The finding of a biased
trough level prediction is probably the result of entry of
values of amikacin levels less than 0,8 mg/l as 0,4 mgll
in the predictive model, but appears to. be of little clini-
cal significance as 94% of the trough amikacin levels
were in the non-toxic range. The three toxic trough
levels in this study occurred in a patient with rapidly
deteriorating renal failure who subsequently died.
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